Can-Fite BioPharma Ltd. (CANF) Analysts See $-0.14 EPS

March 15, 2018 - By Marie Mckinney

 Can Fite BioPharma Ltd. (CANF) Analysts See $ 0.14 EPS

Analysts expect Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) to report $-0.14 EPS on March, 30.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.14 EPS. After having $-0.04 EPS previously, Can-Fite BioPharma Ltd.’s analysts see 250.00 % EPS growth. The stock decreased 3.77% or $0.06 during the last trading session, reaching $1.53. About 78,407 shares traded. Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) has declined 27.09% since March 15, 2017 and is downtrending. It has underperformed by 43.79% the S&P500.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company has market cap of $29.43 million. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It currently has negative earnings. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

More important recent Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) news were published by: which released: “CANF: Take Multiple Shots on Goal With Can-Fite BioPharma” on March 18, 2015, also published article titled: “Can-Fite Biopharma Ltd. ADR”, published: “Can-Fite’s Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III …” on August 02, 2016. More interesting news about Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was released by: and their article: “News Can-Fite Biopharma Ltd. ADRCANF” with publication date: November 19, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.